Microbiome company Finch raises $53M ahead of anti-infective readout

Finch's series C round is designed to carry the microbiome company through what could be a pivotal data readout next year in Clostridium difficile infection, while also allowing it to continue building on a pair of platforms that deliver bacterial cocktails to the gut.

In a round announced Thursday, Finch Therapeutics Group Inc. raised $53 million from new investors OCV Partners, Susquehanna International Group, Symbiosis and the Trans-Pacific Technology Fund, as well as existing investors Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors...